SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Abstract

Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

1 - 33 . (canceled) 
     
     
         34 . A compound selected from the group consisting of:
 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one;   6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one;   1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one;   and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides thereof.   
     
     
         35 . The compound of  claim 34 , wherein the compound is 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         36 . The compound of  claim 34 , wherein the compound is 6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         37 . The compound of  claim 34 , wherein the compound is 1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         38 . The compound of  claim 34 , wherein the compound is 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt thereof. 
     
     
         39 . The compound of  claim 34 , wherein the compound is 6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt thereof. 
     
     
         40 . The compound of  claim 34 , wherein the compound is 1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one or a pharmaceutically acceptable salt thereof. 
     
     
         41 . The compound of  claim 34 , wherein the compound is 1-[2-(Azetidin-1-yl)-2-oxo-ethyl]-3-methyl-6-[5-(trifluoromethyl)-2-thienyl]imidazo[4,5-b]pyridin-2-one 
     
     
         42 . The compound of  claim 34 , wherein the compound is 6-(3-Methoxyphenyl)-1-[2-oxo-2-(2-thienyl)ethyl]-3H-imidazo[4,5-b]pyridin-2-one 
     
     
         43 . The compound of  claim 34 , wherein the compound is 1-(3,3-Dimethyl-2-oxo-butyl)-6-[3-(trifluoromethyl)phenyl]-3H-imidazo[4,5-b]pyridin-2-one 
     
     
         44 . A pharmaceutical composition comprising the compound of  claim 35  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         45 . A pharmaceutical composition comprising the compound of  claim 36  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         46 . A pharmaceutical composition comprising the compound of  claim 37  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         47 . A pharmaceutical composition comprising the compound of  claim 38  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         48 . A pharmaceutical composition comprising the compound of  claim 39  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         49 . A pharmaceutical composition comprising the compound of  claim 40  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof and at least one pharmaceutically acceptable excipient. 
     
     
         50 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 35  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         51 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 35  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         52 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 36  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         53 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 36  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         54 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 37  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         55 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 37  or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof. 
     
     
         56 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 38  or a pharmaceutically acceptable salt thereof. 
     
     
         57 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 38  or a pharmaceutically acceptable salt thereof. 
     
     
         58 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 39  or a pharmaceutically acceptable salt thereof. 
     
     
         59 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 39  or a pharmaceutically acceptable salt thereof. 
     
     
         60 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 40  or a pharmaceutically acceptable salt thereof. 
     
     
         61 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 40  or a pharmaceutically acceptable salt thereof. 
     
     
         62 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 41 . 
     
     
         63 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 41 . 
     
     
         64 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 42 . 
     
     
         65 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 42 . 
     
     
         66 . A method of treating a subject suffering from or diagnosed with treatment-resistant depression, comprising administering to the subject an effective amount of the compound of  claim 43 . 
     
     
         67 . A method of treating a subject suffering from or diagnosed with major depressive disorder, comprising administering to the subject an effective amount of the compound of  claim 43 .